Table I.
Clinicopathological characteristics of the 125 breast cancer patients.
| Characteristics | Number of patients, no. (%) (n=125) |
|---|---|
| Mean age, years | 53.4 |
| Mean BMI, kg/m2 | 28.6 |
| Race | |
| Caucasian | 90 (72.0) |
| African-American | 13 (11.0) |
| Hispanic | 19 (15.0) |
| Other | 3 (2.0) |
| Postmenopausal | 84 (68.0) |
| Tumor size | |
| T1a | 39 (31.2) |
| T2b | 53 (42.4) |
| T3c | 10 (8.0) |
| T4d | 23 (18.4) |
| Axillary LN metastasis | 68 (54.4) |
| High-grade tumore | 60 (48.8) |
| LVI | 42 (34.7) |
| ER | 76 (60.8) |
| PR | 64 (51.2) |
| HER-2/neu amplification | 18 (14.4) |
| TNBCf | 35 (28.0) |
| NACT | 42 (34.7) |
| COX-2 expression (n=106)g | 35 (33.0) |
| Ki-67 (n=51)h | 27 (52.9) |
a
≤2 cm.
b
>2 and ≤5 cm.
c
>5 cm.
d
Any tumor size, but extending to the overlying skin or chest wall.
e
Grade 3.
f
Absence of ER and PR positivity and HER2 gene amplification.
g
Presence of COX-2 expression in ≥5% of cells as determined by immunohistochemistry.
h
≥35% of tumor cells exhibiting Ki-67 staining.
BMI, body mass index; LN, lymph nodes; LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; NACT, neoadjuvant chemotherapy; COX-2, cyclooxygenase-2.